Company intelligence / Profile preview

Inverseon

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Inverseon's lead program, INV102 (oral beta blocker, likely a carvedilol derivative), completed two Phase IIa proof-of-concept studies in asthma with additional Phase II work aiming to demonstrate efficacy in smoking cessation and chronic bronchitis. The approach is supported by basic science on chronic beta-blockade and highlighted in The Lancet[1][2][3].

Therapeutic areas: PsychiatryCardiovascularPulmonology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Inverseon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inverseon.

Explore the full profile